Fresenius reports Q3 beat thanks to Kabi growth in emerging markets


Oct 29 (Reuters) - German healthcare group Fresenius FREG.DE beat third-quarter revenue forecasts on Tuesday as softer revenue growth in North America was offset by growth of its infusions drugs unit Kabi in emerging markets.

The group confirmed its full-year guidance after third-quarter revenues rose by 8% to 8.9 billion euros in the third quarter, compared to 8.7 billion euros in a company-compiled consensus.

(Reporting by Zuzanna Szymanska in Gdansk Editing by Tomasz Janowski)

((; + 48 58 778 52 86;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.